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ABSTRACT 
Large population-based studies have helped to identify cardiovascular risk factors and to 
understand the natural progression of diseases. Cardiac magnetic resonance (CMR) is the reference 
method for the assessment of ventricular morphology and function given the low variance between 
scans. In addition, advanced sequences such as MR tagging, T1 mapping, and late gadolinium 
enhancement allow to assess regional ventricular function and fibrotic changes. MESA was the 
first study to use CMR on a large scale in a sample of the general population. Subsequent studies 
focused on cohorts of particular ethnicities or from certain locations with the Jackson Heart Study 
looking at African-Americans and the Dallas Heart Study at Dallas County Residents. More 
recently, the German National Cohort and UK Biobank have started to perform CMRs in a 
significantly larger number of participants (30,000 and 100,000, respectively). The introduction of 
CMR into prospective cohort studies has allowed to characterize ventricular remodeling in 
individuals of different age, sex, and gender and has found associations with new environmental 
exposures. The ability to detect subclinical changes in asymptomatic individuals has also been 
highlighted by reports of a high number of missed myocardial infarctions (MI) using CMR. In this 
review, we discuss the use of CMR in the different large population-based studies and compare 
the various associations found with left and right ventricular structure and function. In addition, 
we outline automated image analysis strategies aimed at overcoming challenges posed by the large 
amount of data in population-based studies. 
 
Keywords: CMR; cardiac magnetic resonance; cohort studies; population-based studies 
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INTRODUCTION 
Chronic cardiovascular diseases such as myocardial infarction or heart failure are associated with 
significant morbidity and mortality. Prospective cohort studies help to identify risk factors 
associated with the development of those conditions and may allow to characterize high risk 
individuals for targeted intervention. Early cohort studies such as the Framing Heart Study 
characterized major cardiac risk factors including smoking[1] and different hypertension 
phenotypes[2]. More recent studies also include different cardiac imaging techniques including 
coronary artery calcium scores, echocardiography and cardiac magnetic resonance (CMR)[3,4] in 
addition to the standardized questionnaires and exams. These approaches have allowed to 
characterize early changes in cardiac phenotypes and to find novel associations with cardiac risk 
factors[5]. Further, they have helped to prognosticate long-term outcomes based on specific 
imaging biomarkers[6]. 
 
This review describes the use of CMR across large-scale prospective population studies, highlights 
novel associations found in the setting of the wide application of those imaging techniques, and 
discusses novel automated image analysis strategies to overcome challenges posed by the large 
amount of data obtained in population-based studies.  
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 4 
LARGE-SCALE PROSPECTIVE POPULATION STUDIES THAT HAVE USED CMR 
Patient selection and follow up 
The first prospective cohort study to use CMR to study cardiac morphology and function was the 
Multi-Ethnic Study of Atherosclerosis (MESA)[7]. It included a total of 6,814 asymptomatic 
individuals aged 45-84 who have been followed since 2000-2002[8]. The study included 
participants of four different ethnicities: Approximately 38% are white, 28% are African-
American, 22% are Hispanic, and 12% are Asian. CMR was performed on 5,004 participants at 
baseline. 3,016 participants also underwent a repeat CMR after approximately 10 years, making it 
the only large population-based study allowing to study longitudinal changes in cardiac 
morphology and function. Of note, repeat CMR scans were performed with steady-state free 
precession (SSFP) cine sequences, while a gradient echo (GRE) cine sequence was used as 
baseline. The study’s CMR protocol is also notable for the additional use of intra-venous (IV) 
contrast which allowed to better characterize myocardial fibrosis using T1 mapping and late 
gadolinium enhancement [9]. In addition, MR tagging was performed, a technique that is used to 
evaluate regional myocardial function. 
 
While MESA included participants of different ethnicities, the Jackson Heart Study investigated 
cardiovascular disease (CVD) risk factors exclusively in African-Americans, a group with higher 
rates of CVD and cardiovascular (CV) risk factors than the general population[10]. The study 
consisted of 5,301 men and women enrolled between 2000 and 2004 [11]. 1,672 participants 
underwent CMR around 9 years after the baseline visit. Similar to MESA, contrast-enhanced MRI 
was performed, but only in a subset of individuals with CMR. 
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 5 
The discrepancies between different ethnicities were further studied in the Dallas Heart Study, a 
multiethnic cohort which enrolled 6,101 Dallas County Residents between 2000 and 2002 [12,13]. 
African-Americans were oversampled to represent 50% of the final cohort. CMR was performed 
on a sample of 2,971 participants aged 30-65. Of note, the study was later transformed from a 
cross-sectional into a longitudinal study and is still ongoing, but CMR has not been repeated. 
 
The two epidemiological studies with the highest number of participants are the UK Biobank and 
the German National Cohort. Both are in their early phases. The UK Biobank recruited more than 
500,000 men and women aged 40-69 between 2006 and 2010 in the UK[4]. A random subset of 
those participants have been invited back for comprehensive imaging visits including a CMR 
examination with the goal to perform 100,000 CMR scans by 2023 [14]. The German National 
Cohort is currently recruiting 200,000 participants of the general population aged 20-69. 30,000 
randomly selected participants are undergoing whole-body MRI at the baseline visit and possibly 
at a follow-up visit 4-5 years later[15,16]. Neither of those studies is performing contrast-enhanced 
CMR. The German National Cohort is, however, the only large population-based study that will 
use 3 Tesla MRI machines for CMR. 
 
Other cohort studies that performed CMR include the Study of Health in Pomerania (SHIP)[17], a 
study of residents in the German region Pomerania, Age, Gene/Environment Susceptibility 
(AGES)-Reykjavik[18], a study of Icelanders, Prospective Investigation of the Vasculature in 
Uppsala Seniors (PIVUS)[19], and the Framing Heart Study Offspring cohort[20]. While CMR 
scanning has been completed for all of these studies, clinical follow up is still ongoing. Large 
cohort studies that are being planned or that are in their very early stages are the Hamburg City 
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 6 
Health Cohort Study[21] and the Canadian Alliance of Healthy Hearts and Minds[22]. Further 
details are summarized in Table 1. 
 
Table 1. Large-scale cohort studies (>1,000 participants) that have used CMR.  
Study Population CMR 
participants 
Time of 
CMR 
CMR protocol Length of follow 
up since CMR 
imaging 
MESA[3,7,2
3] 
6,814 asymptomatic 
men and women (ages 
45-84) of 4 different 
ethnicities without 
known CVD 
Baseline: 
5,004  
Follow up: 
3,016 
(completed) 
At baseline 
visit and 
after ~10 
years (2010-
2012) 
1.5T. LV / RV cine images, 
MR tagging, LGE, MOLLI, 
phase-contrast flow images of 
the ascending aorta, images of 
the carotid arteries.  
Ongoing  
Jackson 
Heart 
Study[11,24
] 
5,301 African-
Americans (ages 35-
84) residing in 
Jackson, MS 
1,672, 600 
with IV 
contrast 
(completed) 
Between 
2008-2012 
(~8 years 
after 
baseline 
visit) 
1.5T. LV / RV cines, MR 
tagging, contrast sequences, 
aortic structure and function 
Visit 1 2000-2004, 
visit 2 2005-2008,  
visit 3 2009-2012 
Dallas Heart 
Study[12] 
6,101 Dallas County 
Residents (ages 18-
65). Participants 
undergoing imaging 
were ages 30-65. 
2,971 
(completed) 
At baseline 
visit in 2000-
2002 
1.5T. LV / RV cines, phase-
contrast gradient echo 
sequence of aorta 
Ongoing 
UK 
Biobank[4,2
5] 
>500,000 men and 
women (aged 40-69) of 
the general population 
Goal 100,000 
(ongoing) 
Several 
years 
following 
the baseline 
visit 
1.5T. LV / RV cines, MR 
tagging, aortic flow 
sequences, native T1, aortic 
distensibility 
Ongoing 
German 
National 
Cohort[15,1
6,26] 
200,000 men and 
women (aged 20-69) of 
the general population 
Goal 30,000 
(ongoing) 
Baseline 3T. LV / RV cines, native 
angiography, parametric T1 
mapping 
Ongoing 
SHIP[17,27,
28]  
6,753 men and women 
(aged 20-79) of the 
general population of 
Pomerania 
528 contrast-
enhanced 
CMR 
2008-2012 
(at SHIP-2) 
1.5T. LV / RV cines. MRA. 
LGE in men. 
SHIP-0 1997-
2001 
SHIP-1 2002-
2006 
SHIP-2 2008-
2012 
SHIP-3 2014-
2016 
SHIP-
Trend[17,27
,28] 
4,420 men and women 
(aged 20-79) of the 
general population of 
Pomerania 
997 contrast-
enhanced 
CMR 
2008-2012 
(at baseline 
visit) 
1.5T. LV / RV cines. MRA. 
LGE in men. 
SHIP-Trend 2008-
2012 
SHIP-Trend-1 
Since 2016 
Canadian 
Alliance of 
Healthy 
Hearts and 
Minds[22] 
9,700 male and female 
Canadians aged 35-69  
All 9,700 
participants 
Baseline Standard CMR: LV / RV 
cines. 
Extended CMR: LV / RV 
cines. MR tagging. Phase-
contrast cine. LGE. T1 
mapping. T2 star-weighted 
sensitive sequence. 
Ongoing 
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 7 
CMR, cardiac magnetic resonance; CVD, cardiovascular disease; LV, left ventricle; RV, right 
ventricle; LGE, late gadolinium enhancement; MOLLI, modified Look-Locker inversion 
recovery; IV, intra-venous; T, Tesla; SHIP, Study of Health in Pomerania; AGES, Age, 
Gene/Environment Susceptibility; PIVUS, Prospective Investigation of the Vasculature in Uppsala 
Seniors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGES-
Reykjavik 
Study[18] 
5,764 Icelanders born 
between 1907 and 
1935 
936 as part of 
the 
ICELAND 
MI cohort 
(completed) 
~40 years 
after initial 
enrollment 
in AGES in 
1967 
1.5T. LV / RV cines. LGE. Ongoing  
Hamburg 
City Health 
Cohort 
Study[21] 
45,000 inhabitants 
(aged 45-74) of the city 
of Hamburg, Germany 
12,362 
(planned) 
Baseline 1.5T. LV / RV cines. LGE. 
Mapping. Aortic / mitral flow 
measurements. Angiography. 
Aortic distensibility. 
Ongoing 
PIVUS 
study[19] 
1,016 residents in the 
municipality of 
Uppsala, Sweden 
(aged 70 and over) 
259 
(completed) 
3-22 months 
after primary 
investigation  
1.5T. LV cines. LGE. MRA.  Completed 
Framingham 
Heart Study 
Offspring 
Cohort[20,2
9] 
5,135 residents of 
Massachusetts, 
offspring of original 
FHS cohort 
1,837 
(completed) 
~30 years 
following 
initial 
evaluation 
1.5T. LV / RV cines.  Ongoing 
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CMR imaging and power of study 
There are three factors that affect the power of the study: (i) prevalence of exposure, (ii) prevalence 
/ incidence of outcome, and (iii) number of CMR scans performed. While the number of CMR 
scans is readily available, the former two factors might easily be overlooked. 
 
The closer the prevalence of the exposure and outcome is to 50%, the higher is the power of the 
study. This becomes important when looking at the different research questions cohort studies 
using CMR have tried to answer. Most studies focus on either cardiac structure and function as 
outcome parameters and try to determine which cardiac risk factors are associated with different 
cardiac phenotypes, or they try to find imaging biomarkers that are associated with the future 
outcome of the patient (using cardiac structure and function as assessed by CMR as exposure). 
Certain cardiac risk factors such as hypertension may be present in up to 40% of the population 
[30], making it relatively easy to find associations with CMR outcomes. Clinical outcomes such 
as myocardial infarction may, however, only occur in <1% of the population per year[30], 
requiring either a higher number of CMR scans or a longer follow up. Tables 2 and 3 show the 
lowest odds ratios (OR) that are detectable with a power of 80% by the prevalence of the exposure 
and the number of CMR scans performed as part of the study. 
 
For Table 2, the prevalence of the outcome was assumed to be 4%, while it was assumed to be 2% 
for the calculations in Table 3. So far, the largest study that has been completed remains the MESA 
study with 5,000 CMR scans. When investigating the association between a risk factor such as 
diabetes mellitus, which has been found to be present in approx. 2.5% in the general 
population[31], and an imaging marker that is present in approximately 4% of the general 
population, the lowest OR the MESA study could detect would be 2.61, whereas the UK Biobank 
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will be able to detect an OR as low as 1.30. Even more pronounced are the differences when it 
comes to associations between CMR findings and long-term clinical outcomes. When 
investigating an association between an imaging biomarker that is present in 2.5% of participants 
and a cardiovascular outcome such as myocardial infarction, the lowest detectable OR of the 
MESA study and the UK Biobank would be 3.36 and 1.43, respectively. Those calculations assume 
that 2% of participants have had a myocardial infarction (MI). The power of the study can be 
increased through longer follow-up periods, although at a risk of selection bias due to drop out. 
 
 
 
Table 2. Lowest detectable OR with a power of 80% assuming a baseline prevalence of the 
outcome of 4%. 
 Prevalence of exposure 
# of CMR scans 2.5% 5% 10% 20% 
1,000 5.62 3.93 3.00 2.43 
2,000 3.87 2.88 2.30 1.95 
5,000 2.61 2.09 1.77 1.56 
10,000 2.07 1.74 1.52 1.39 
30,000 1.58 1.41 1.29 1.22 
100,000 1.30 1.22 1.16 1.12 
OR, odds ratio; CMR, cardiac magnetic resonance. 
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Table 3. Lowest detectable OR with a power of 80% assuming a baseline prevalence of the 
outcome of 2%. 
 Prevalence of exposure 
# of CMR scans 2.5% 5% 10% 20% 
1,000 7.88 5.38 3.99 3.15 
2,000 5.25 3.78 2.92 2.39 
5,000 3.36 2.59 2.11 1.81 
10,000 2.55 2.06 1.75 1.55 
30,000 1.83 1.58 1.41 1.31 
100,000 1.43 1.30 1.22 1.16 
OR, odds ratio; CMR, cardiac magnetic resonance. 
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ASSOCIATIONS WITH LV STRUCTURE AND FUNCTION 
The relationship of sex and age with CMR based outcomes has been widely studied across the 
different cohorts. Among individuals without overt cardiovascular disease, male sex has repeatedly 
been linked to greater left ventricular (LV) volumes and mass. LV ejection fraction (EF) has, 
however, consistently been found to be higher in women than in men [20,32–34]. While the results 
of different cohorts indicate that LV volumes decrease with age [32,34,35], striking differences 
are seen between cross-sectional and longitudinal changes in LV mass: In the cross-sectional 
analysis of the UK Biobank, no association was seen between age and LV mass [32], findings 
similar to those in the SHIP study [27]; a cross-sectional analysis of the baseline data of MESA 
found an inverse relationship between age and LV mass [36]; and a longitudinal increase in LV 
mass was seen between the MESA baseline and follow up visits [37].  
 
One possible explanation is that those differences are due to selection bias given that only 
individuals without overt cardiovascular disease at baseline were included in the MESA study - 
older participants without cardiovascular disease at baseline are likely different from younger 
participants as they had to be able to remain healthy despite a longer exposure to cardiovascular 
risk factors. While a longitudinal analysis of the Framingham Heart Study also found an increase 
in LV mass in men using echocardiography, it also found a longitudinal increase in LV mass in 
women [38], further complicating the interpretation of the results and also highlighting difficulties 
when comparing CMR to – especially 2D – echocardiography. Physiologically, a follow-up study 
provided some insight into potential mediators of the effect of age on LV mass: Subramanya et al. 
[39] found that higher free testosterone levels and lower sex hormone binding globulin levels (i.e. 
more androgenic profiles) were associated with higher LV mass in both men and women. 
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Independently of the cause of the intriguing LV mass findings, it seems clear that LV mass to 
volume ratio (LVMR), a marker of adverse remodeling [40], increases over time.  
 
MESA’s unique design makes it ideal for comparisons of different ethnicities. LV mass and 
volumes were lower among Asian Americans compared to white Americans, African Americans, 
and Hispanics for both men and women [33]. In addition, Hispanics were found to have a higher 
prevalence of both concentric and eccentric LV remodeling and LV hypertrophy (LVH). The 
association with LVH remained significant for Mexican-origin and Caribbean-origin Hispanics 
even after adjustment for all covariates including a higher proportion of elevated blood pressures 
[41]. The different population-based studies have also allowed a detailed analysis of the effect of 
various CVD risk factors on the cardiac structure and function among the different cohorts. Using 
the Jackson Heart Study, Kamimura et al. [42] recently demonstrated the deleterious effect of 
cigarette smoking on LV mass and function among African Americans. Similar findings have been 
described in the UK Biobank [43] and MESA [44]. 
 
Many of the other traditional CV risk factors and their associations with CMR parameters in 
population cohort studies have been reviewed previously [44,45]. Notably, cohort studies using 
CMR were able to extend prior reports by demonstrating that various inflammatory markers are 
associated with worse cardiac function [46]. High-sensitivity CRP [47], homocysteine [48], and 
fibrinogen [49] were associated with systolic myocardial function even in asymptomatic 
individuals, emphasizing the role of inflammation in the pathogenesis of cardiac dysfunction. 
Several other inflammatory markers including IL-6, soluble thrombomodulin, Factor VIII, and 
vWF have been found to be associated with LV mass [46]. Of note, in this MESA study elevated 
Page 12 of 54AUTHOR SUBMITTED MANUSCRIPT - PRGB-100005.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 13 
CRP and IL-6 were negatively associated with LV mass after adjustment for obesity, indicating a 
mediating effect. 
 
A unique advantage of the large cohorts lies in the ability to study associations between 
environmental exposures and precise and reproducible CMR measurements. One UK Biobank 
study sought to examine the relationship between ambient air pollution and cardiac structure and 
function in 3,920 individuals free from pre-existing CVD [50]. Spatial variations of average annual 
concentrations of particulate matters of different sizes, nitrogen dioxide, and nitrogen oxides were 
calculated for the participant’s home addresses. The adjusted analysis was notable for a significant 
association between higher concentration of particulate matter and larger ventricular volume 
(changes that have been linked to a higher risk of heart failure [51]) with the results indicating that 
the association was predominantly driven by finer particles. A similar association was found for 
nitrogen dioxide, but not for nitrogen oxide. The study highlights how CMR can be used in 
population-based studies to discover biological pathways and to identify high-risk populations. 
 
More recently, population-based cohort studies have also helped to understand cardiac side effects 
of commonly used medications. One MESA study examined the association between H2 receptor 
antagonists and changes in LV morphology [52], a relationship that had previously mostly only 
been studied in animal models. Another MESA study looked at new statin use and cardiac 
remodeling [53] and a UK Biobank study evaluated the impact of menopausal hormone therapy 
(MHT) in post-menopausal women free of CVD [54]. Compared to non-users, H2 receptor 
antagonist users had fewer detrimental changes in LV parameters. They had a smaller decline in 
LV volumes, a smaller decline in LV stroke volume, and a smaller increase in mass/volume ratio. 
Similarly, new statin therapy was associated with less progression of LV mass index and 
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mass/volume ratio, though the effects were small in magnitude. The effect sizes increased as the 
statin dose increased. MHT>3 years was associated with significantly smaller ventricular volumes 
and stroke volumes. As described above, smaller ventricular volumes may be associated with more 
favorable outcomes.  
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CMR TAGGING AND STRAIN ANALYSIS 
CMR tissue tagging allows to quantify parameters of cardiac physiology such as myocardial strain, 
strain rate, and torsion [55]. Strain represents either segment shortening (longitudinal or 
circumferential strain) or thickening (radial strain) and is typically expressed as the fractional 
change from the original dimension. Temporal integration of strain rate is used to calculate 
regional strain. Strain rate, a rate of change of deformation, is derived as a spatial derivative of 
velocity. Circumferential strain is often measured separately at the base, mid-segments, and the 
apex. Torsion describes the relative rotation of short-axis sections between diastole and systole 
[55]. While several population-based cohort studies are planning to include tagging, so far only 
MESA has been used to examine associations with risk factors, cardiac structure, and long-term 
outcomes [56] as described in a review by Yoneyama et al [44]. 
 
CMR tagging in MESA has provided further insight into longitudinal changes in cardiac function. 
As detailed above, while ventricular volumes increase in both sexes, LV mass increases 
longitudinally in men, but decreases longitudinally in women. In contrast, the association with LV 
circumferential strain is the opposite (it decreases longitudinally in men and increases in women) 
[57]. Torsion was found to increase with age in both sexes and could be an important compensatory 
mechanism to counter remodeling and maintain global systolic function.  
 
Notably, in addition to insights into the physiology behind alterations in strain patterns, the study 
[57] highlights another important issue: the need for similar investigations in different population-
based studies even if the individual cohorts are large and reliable techniques such as CMR are 
used. This is illustrated by another positive finding in the study: A V-shaped relationship between 
change in LV mass/volume ratio and change in torsion, a rather new and not immediately intuitive 
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finding. The findings are difficult to interpret because of the use of non-standard measure of 
torsion. Rather than twist per unit length of the ventricle which doesn’t scale appropriately between 
hearts of different sized, the torsional shear angle or shear strain should be calculated [58]. In 
addition, the p-value of those results is 0.02 and therefore reaches statistical significance based on 
the standard 0.05 cutoff. In reality, however, it is almost entirely unclear what those results actually 
mean. Using a Bayesian approach, it can be shown that it all depends on the prior probability and 
that even if we assume that to be close to 50% in the absence of comparable cohort studies, the 
final probability of a true null is well above 10% (and in practice likely even higher than that) [59]. 
The abundance of observable associations should therefore always be viewed cautiously, 
especially in the absence of comparable analyses from other cohorts. 
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ADDITIONAL BENEFIT OF IV CONTRAST IN POPULATION-BASED STUDIES 
In addition to classic applications such as angiography, IV contrast allows for the identification of 
myocardial fibrosis. Post-contrast T1 mapping, a relatively new technique, has been used to assess 
diffuse interstitial fibrosis, a marker of cardiac remodeling [60]. Post-contrast T1 mapping detects 
extracellular volume (ECV) expansion [61], a finding that can be associated with a variety of 
conditions including myocarditis, which lead to myocardial edema [61]. However, in the absence 
of these pathologies, it can be presumed that ECV expansion is the result of increased interstitial 
fibrosis [62].  
 
While several different post-contrast T1 mapping sequences exist, the modified Look-Locker 
inversion recovery (MOLLI) sequence has been used most widely in population-based studies 
using CMR [63,64]. The findings in MESA that women tend to have higher ECV fractions and 
that CMR parameters suggestive of fibrosis tend to be associated with older age [64] have 
previously been summarized [44]. Notable additional findings include the inverse associations 
between extracellular expansion and ventricular volumes, mass, and reduced circumferential strain 
in men and women (torsion and LV EF were only negatively associated in men, whereas strain 
rate was only inversely associated in women) [63]. More recently, a borderline significant 
association was found between inflammatory markers IL-6 and CRP and diffuse fibrosis in men 
[65], while no association was found between the extent of LV trabeculation and markers of diffuse 
fibrosis [66]. 
 
Late gadolinium enhancement on the other hand can be used to detect focal myocardial fibrosis 
and the anatomical pattern can be used to differentiate ischemic from non-ischemic etiologies [67]. 
This technique has been used in the ICELAND-MI cohort to detect unrecognized myocardial 
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infarction [18]. More recently, Shanbhag et al. [68] extended those prior findings by also 
investigating the prevalence of non-ischemic myocardial fibrosis. In their study, 23.4% of 
participants had radiologic evidence of a prior MI, while major and minor non-ischemic patterns 
of fibrosis were seen in 6.0% and 26.4%, respectively. Compared to patients with prior MI, non-
ischemic fibrosis was associated with a higher LV mass, but a lower coronary artery calcium score 
and a lower prevalence of diabetes type II. Interestingly, while the prevalence of recognized and 
unrecognized myocardial infarction in ICELAND-MI was very similar to prior findings in PIVUS 
[69], it was much higher than that in MESA [70]. These differences may be due to demographics 
(ICELAND-MI participants were older with a higher prevalence of cardiac risk factors) and the 
study design (MESA excluded individuals with baseline clinical cardiovascular disease).  
 
In addition to identification of fibrosis, CMR with IV gadolinium allows for myocardial perfusion 
imaging, a technique that allows to reliably detect coronary artery disease (CAD) when compared 
to other non-invasive imaging modalities [71] as well as invasive studies including coronary 
angiography and fractional flow reserve [72]. Perfusion CMR was performed in a subset of the 
MESA patients at rest and during adenosine-induced hyperemia to determine the perfusion reserve 
(the ratio of myocardial blood flow during hyperemia to rest)[73]. In a MESA study of participants 
without known coronary heart disease (CHD), several well-known risk factors of CHD, including 
hypertension and higher LDL cholesterol, were associated with lower perfusion reserve [73]. 
These findings were extended by another study showing that higher coronary artery calcium scores 
are inversely correlated with perfusion reserve, again population-based imaging can help 
identifying subclinical disease and high risk individuals [74], an implication further corroborated 
by the finding that lower perfusion reserve is associated with decreased regional systolic function 
even in asymptomatic participants [75]. 
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IMAGING BIOMARKERS AND OUTCOME PREDICTIONS 
MESA, ICELAND-MI, and the Framingham Heart Study have studied clinical outcomes 
following CMR. It has repeatedly been shown that an elevated LV mass and LVH are associated 
with incident heart failure, coronary heart disease, and cardiovascular death [76–78], a finding that 
is in line with prior studies using echocardiography [79]. Conversely, a normal CMR has been 
associated with a lower risk of incident heart failure [80]. Peters et al. [81] recently extended prior 
reports by showing that individuals with LVH and positive serum biomarkers of myocardial strain 
constitute the group at highest risk for new asymptomatic LV dysfunction, heart failure, and 
cardiovascular death.  
 
Interestingly, despite the differences seen in cardiac remodeling over time between men and 
women as detailed above, the association of LV mass or LV mass/volume with incident 
cardiovascular disease did not differ between men and women [77]. There is, however, evidence 
for racial differences. Akintoye et al. [82] found that the relationship between LV mass and 
incident cardiovascular disease was strongest among Chinese and Hispanics, and weakest for non-
Hispanic Whites. 
 
An analysis of the Framingham Heart Study Offspring Cohort [78] showed, similar to the MESA 
studies, that higher LV mass is associated with a higher incidence of cardiovascular disease. LV 
wall thickness was also associated with the clinical outcomes in that study, while LV wall/volume 
ratio was only borderline significant. Further, the study highlighted how, in addition to trying to 
find causal relationships, large population-based studies that use advanced imaging techniques can 
improve the prediction of clinical outcomes, an application that has also been described using 
MESA [83]. 
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More recently, CMR tagging, late gadolinium enhancement, and T1 mapping as described above 
have also been associated with clinical outcomes [68,84,85]. An ICELAND-MI study [68] 
examined the association of ischemic and non-ischemic myocardial fibrosis identified using late-
gadolinium enhancement and heart failure hospitalization and death from any cause. Patients with 
an MI had, on average, a higher amount of fibrosis. Despite this, the group with major non-
ischemic fibrosis had the highest rates of heart failure hospitalizations compared to patients with 
ischemic fibrosis, minor non-ischemic fibrosis, or no fibrosis after adjustment for confounders. 
The authors highlight the important implication that the pathophysiologic processes leading to 
non-ischemic fibrosis are not captured by the traditional risk factors they adjusted for in the 
analysis.  
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ASSOCIATIONS WITH RV STRUCTURE AND FUNCTION 
One of the biggest strengths of CMR is its ability to accurately characterize the right ventricle 
(RV), which has made it possible to investigate risk factors associated with RV dysfunction and 
remodeling: Cross-sectional analyses of the Framingham Heart Study Offspring Cohort [86] and 
MESA [87] have shown that RV mass decreases with age and that men have greater RV mass and 
larger RV volumes, but lower RV EF. Aaron et al. [88] demonstrated that physical activity is 
associated with higher RV mass and volume. And while obesity has also been found to be 
associated with higher RV mass and volume [89], the RV EF was lower in obese than in lean 
individuals. 
 
One of the risk factors specifically linked to RV dysfunction is pulmonary dysfunction. While it 
has been known from other cohort studies that chronic pulmonary disease is associated with a 
higher rate of adverse cardiac outcomes [90], population-based studies using CMR have helped to 
identify underlying pathways and to characterize subclinical changes in cardiac structure and 
function. One MESA study sought to examine the association of emphysema with RV changes 
using the lung density on cardiac CT scans to determine the severity of the emphysema [91]. 
Greater percent of emphysema was associated with lower RV end-diastolic volume, stroke 
volume, cardiac output, and mass. The magnitude of those changes was greater among current and 
former smokers compared to never smokers. Thomson et al. [92] extended those findings by 
showing that reduced forced expiratory volume (FEV1) and forced vital capacity (FVC) are 
associated with lower RV end-diastolic volume, end-systolic volume, and lower stroke volume in 
a sample of the UK Biobank cohort without known cardiorespiratory disease. 
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Similar to the LV, the RV structure and function has also been associated with several commonly 
used medications. Histamine 2 (H2) receptor antagonists were associated with a lower RV mass 
and smaller RV volume, while the ejection fraction was unchanged [93]. These results remained 
significant after adjustment for left ventricular mass, indicating a potential favorable effect on RV 
morphology that is independent of the effect on the LV described above. Selective serotonin 
reuptake inhibitors (SSRIs), on the other hand, have been found to be associated with larger RV 
stroke volume without a change in RV EF [94]. Interestingly, RV mass and RV end-diastolic 
volume were higher in men on SSRIs, a finding that is unexpected given a the expected protective 
effect of SSRIs against serotonin induced pulmonary hypertension [95]. The cross-sectional design 
and lack of adjustment for length of therapy, however, are considerable limitations. The 
association between angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARB) and RV structure and function remains similarly unclear. While a MESA study 
found significant associations with RV mass and volumes [96], the study failed to adjust for the 
high number of tests performed and adjusted for LV measures which are possibly on the causal 
pathway given the known effect of ACE inhibitors and ARBs on LV morphology and function. 
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NOVEL APPROACHES TO IMAGE ANALYSIS – AUTOMATION IN POPULATION-BASED 
STUDIES 
A major challenge for population-based studies is the analysis of the large amount of imaging data. 
The analysis of the CMR scans in clinical practice and the population-based studies discussed 
above heavily relies on manual approaches to identify cardiac chambers and blood vessels. This 
process is prone to subjective variation and is very time-consuming, requiring up to 30 minutes for 
a single CMR analysis of the left and right ventricular volumes. However, population-based studies 
may at the same time offer a solution to the problem by providing large datasets that help to 
improve machine learning algorithms. While the overall number of participants is still small 
compared to other specialties, population-based studies are currently the closest we can get to big 
data in a controlled environment in medical imaging and may allow for the development of 
algorithms for data analytics at large. The following sections will discuss the analysis process, 
which can be divided into a pre-analytical, an analytical, and a post-analytical part.  
 
Pre-analysis quality control 
Prior to segmentation and measurement of cardiac structure and function, it is necessary to ensure 
adequate CMR image quality. Incomplete myocardial coverage, suboptimal angulation or slice 
position, motion artefacts due to breathing or arrhythmia, aliasing, and truncation artifacts are 
some of the issues that may impair the subsequent analysis [97,98]. Initial image quality 
assessment is usually performed by radiographers to ensure that the patient does not leave the 
scanner before diagnostically interpretable images have been obtained. However, this process may 
be subjective and error-prone, and potentially time consuming [99]. Several studies have aimed to 
define standardized criteria for quality control through visual inspection in cardiovascular imaging 
using MRI [100,101], but the process remains very time consuming and challenges such as inter- 
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and intra-reader variability persist. These issues are further compounded when large amounts of 
data are obtained for population-based studies because of different imaging centers involved and 
a lag in time between image acquisition and analysis [102].  
 
In an effort to overcome these limitations, Zhang et al. [102] recently proposed an algorithm for 
the automatic assessment of full left ventricular coverage. The method was validated in 5,000 
CMR scans from the UK Biobank. The algorithm’s error rate was just below 5% and demonstrated 
good agreement with a human expert. Tarroni et al. [103] proposed a strategy based on the 
identification of cardiac landmarks (apex and mitral valve) to estimate heart coverage that was 
able to identify cases in the UK Biobank with insufficient coverage with 88% sensitivity and 99% 
specificity. In addition, their quality control algorithm was designed to assess inter-slice motion 
detection and image contrast estimation in the cardiac region. Motion-corrupted cases were 
detected with a sensitivity and specificity of 85% and 95%, respectively. The complexity of motion 
detection that is caused by respiratory variation alone has been outlined extensively [104,105] and 
is one of the areas where further research is needed to improve automated quality control 
techniques. Others include identification and correction for suboptimal angulation and slice 
position and automated approaches to predicting results from slices that have poor quality of what 
the results would have been with good image quality.  
 
Analysis 
The analysis part includes the identification, localization, and segmentation of cardiovascular 
contours, enabling an automated quantification of the cardiac structure and function. A number of 
(semi-) automated LV segmentation algorithms have been described that include a wide range of 
different techniques [106–111]. There are, however, only a few studies evaluating segmentation 
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algorithms for more advanced techniques such as T1 mapping [112], late gadolinium enhancement 
MR images [113,114], aortic stiffness [115], or aortic flow [116]. In addition, most of them have 
been developed in small datasets, limiting their application in clinical practice or population-based 
studies. 
 
The Siemens InlineVF was one of the first commercially available fully automated LV analysis 
tools and the results of the D13 version are available to researches as part of the original UK 
Biobank dataset. A study comparing automated analyses using the D13 as well as the advanced 
E11C InlineVF versions to manual assessments [117]  showed that the best precision obtainable 
with the automated analysis was about two to three times that of the manual analysis for ventricular 
volumes and mass. The study also highlighted conditions where misdetection is more common: If 
the aorta is very bright or pulsating, if the contrast between blood and myocardium is weak, and if 
the gray level distributions of the different regions cannot be modeled correctly due to unexpected 
intensities and contrast in the images.  
 
Also using the UK Biobank, Bai et al. [118] recently developed a fully convolutional network to 
analyze the 4,875 CMR studies that have already been annotated by clinical experts. The 
automated analysis closely matched the analysis by clinical experts with Dice metrics >0.9. The 
mean differences between automated and manual assessment were only 6.9 for LV mass and <10 
mL for all LV volumes. Automated algorithms have also been found to be able to reliably detect 
the localization of the ascending and descending aorta [119], a step that is vital for the calculation 
of aortic distensibility. Compared to the ground truth (established by visual assessment by 13 
observers), the algorithm was able to detect the ascending and proximal descending aorta with an 
accuracy of 99.4% and 99.8%, respectively. 
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Novel algorithms may also help to provide tools for better quantification of the myocardial 
structure and function. As detailed above, current clinical assessment is mostly limited to 
ventricular mass and volume measures. The Cardiac Atlas Project (CAP) is an international 
collaboration to provide a population atlas of asymptomatic and pathological hearts [120–122], 
which has facilitated the development and sharing of advanced analysis techniques including 
statistical shape modeling. MESA contributed data from the baseline examination of 1,991 
asymptomatic volunteers. Data has also been contributed from several other studies including 
Defibrillators to Reduce by Magnetic Resonance Imaging Evaluation (DETERMINE) [122].  
 
Studies using the CAP data have shown that shape analysis techniques such as principal 
component analysis (PCA) can be used to quantify remodeling due to myocardial infarction 
[123,124] or congenital heart disease [125]. These approaches may help with identifying 
individuals with a certain pathology and, consequently, those at increased risk for adverse 
outcomes. However, the clinical interpretation of PCA shape components is often difficult as they 
are not designed to be related to any of the clinical parameters discussed above. Approaches that 
relate statistical modeling to clinical remodeling parameters might help to overcome this limitation 
[126].  
 
In addition to currently available segmentation techniques for ventricular or atrial volumes, further 
research should focus on the development of highly accurate and precise segmentation tools for 
regional systolic function (strain analysis) and vascular analyses such as aortic stiffness measures 
and flow quantification. In addition, automated analysis algorithms are needed for advanced CMR 
techniques outlined above including late gadolinium enhancement, CMR perfusion, and mapping 
(including T1, T2, T2*, and extracellular volume). 
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Post-analysis quality control 
Earlier work has relied on visual verification of segmentation results, which becomes impractical 
in large population-based studies. In addition to proposing a fully automatic method for initializing 
CMR segmentation, Alba et al. [127] proposed one of the first measures to identify incorrect 
segmentation without the need for visual assessment. Failure is detected using statistical, pattern, 
and fractal descriptors based on features computed on image intensity values of the blood pool and 
myocardium.  Using CAP for verification, the accuracy of the segmentation quality control reached 
96% in both asymptomatic individuals and in individuals with a prior MI.  
 
Automated quality control in image segmentation has also been applied to the UK Biobank 
datasets. Robinson et al. [128] used Reverse Classification Accuracy (RCA) to predict the quality 
of segmentation on a case-by-case basis, allowing not only to identify the quality of the 
segmentation, but also if the segmentation has failed. The algorithm was also successfully applied 
to a large dataset without ground truth and showed good agreement with visual quality control 
scores, simulating real life scenarios. A potential limitation of the approach is the runtime of 11 
minutes as it limits immediate feedback.  
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Table 4. Automation and Quality Control. 
 Pre-Analysis Quality 
Control 
Analysis Post-Analysis 
Quality Control 
Challenges - Incomplete myocardial 
coverage 
- Suboptimal angulation 
- Suboptimal slice position 
- Motion artifacts  
- Aliasing 
- Truncation artifacts 
- Automatic 
quantification of 
cardiac structure and 
function 
- Segmentation 
algorithms for more 
advanced techniques 
(Mapping of T1 / T2 / 
T2* / extracellular 
volume, LGE, CMR 
perfusion, aortic 
stiffness, aortic flow) 
- Advanced analysis 
techniques such as 
statistical shape 
modeling 
- Verify correct 
segmentation without 
need for visual 
assessment 
Examples of 
Current 
Approaches 
- Automatic assessment of 
full LV coverage [102] 
- Assessment of LV 
coverage based on cardiac 
landmarks [103] 
- Assessment of inter-slice 
motion [103] 
- Siemens InlineVF 
LV analysis tool [117] 
- Fully convolutional 
networks for the 
analysis of LV mass 
and volume [118] 
- Statistical shape 
analysis using the 
datasets of the cardiac 
atlas project [123–
126] 
- Combination of 
statistical, pattern, 
and fractal 
descriptors based on 
blood poor and 
myocardium features 
[127] 
- Reverse 
classification 
accuracy [128] 
LGE, Late gadolinium enhancement; CMR, Cardiac magnetic resonance; LV, Left ventricle. 
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FUTURE WORK 
CMR in population-based studies offers a unique opportunity to bring together experts from 
different fields to combine approaches from medicine, epidemiology, engineering, and computer 
science. Improvements in image analysis, automation, and quality control will help advance our 
ability to identify cardiac risk factors and to correlate imaging characteristics with clinical 
outcomes, a process leading to precision medicine that will be most impactful if cohorts are 
combined and data are shared (Figure 1). 
 
Exposures and Clinical Outcomes 
Large population-based studies are ideal to study the effects of rare exposures or exposures that 
vary considerably among individuals of the target population. An example of this is the 
combination of cardiac imaging with genetics: In order to be able to identify new genes that are 
associated with certain cardiac characteristics at a population level, a large number of participants 
needs to be included. Further examples include various environmental exposures such as traffic, 
pollution, noise, or stress. In addition, population-based studies may help to show a benefit 
associated with new technologies aimed at promoting health such as the Apple Watch. Population-
based studies using CMR may also allow the identification of unknown cardiac effects of various 
medications or even the correlation of findings from different imaging techniques. For example, 
the large number of cardiac and brain MRIs obtained on participants of the UK Biobank might 
allow to better understand which cerebral changes are associated with alterations in cardiac 
structure or function. There are many other organ interactions with the heart that are worth 
exploring in an aging population with increasing multi-morbidity and polypharmacy: e.g. 
respiratory-cardiac axis, liver-heart axis or bone-heart axis. All of these questions could be 
answered as soon as MRIs have been obtained on a critical number of participants of the target 
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population if a cross-sectional approach is used. Other questions that seek to answer which cardiac 
phenotypes are associated with certain clinical outcomes such as cardiovascular events, on the 
other hand, will require longer follow up periods.  
 
Image Sequences and Analysis 
The large number of study subjects in population-based studies, time consuming manual analyses, 
and significant inter-reader variability require the development of highly accurate, automated 
segmentation tools for standard measures such as ventricular mass and volume, and for various 
advanced CMR techniques including strain analysis, late gadolinium enhancement, CMR 
perfusion, and mapping. In addition to conventional segmentation of these sequences, further 
development of advanced analysis techniques may allow for a more precise identification of 
individual structural and functional characteristics.  
 
A very promising example of an advanced analysis technique is the extraction of a large number 
of quantitative features from digital images. This process, in combination with the storage in 
shared databases to facilitate subsequent hypothesis generation or testing, is known as radiomics 
[129,130]. While radiomics has thus far mostly been used in the field of oncology [131,132], it 
can be applied to many conditions and will undoubtedly help advance precision medicine by 
identifying and verifying new imaging biomarkers. The process of radiomics as outlined 
previously [129] includes image acquisition, identification of the volume of interest, segmentation, 
extraction and qualification of descriptive features from the volume, and population of a searchable 
database. Application of radiomics to CMR data on a population level will not only allow to better 
characterize subtle changes in the cardiac phenotype which are not immediately obvious using 
standard measures such as LV mass or volume, but it will also allow to improve the prediction of 
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outcomes and thereby potentially provide the means to identify individuals who are most likely to 
respond to a certain intervention. 
 
Finally, the large number of datasets may offer the opportunity to develop algorithms to predict 
the results of sequences which were not directly obtained during an MRI scan. For example, early 
synthetic gadolinium enhancement has been shown to agree with conventional late gadolinium 
enhancement for assessing myocardial scar [133], a finding that may allow to shorten CMR 
acquisition time. Further helpful approaches could for example include the prediction of CMR 
perfusion scans if perfusion imaging was not performed.  
 
Quality Control 
The challenges associated with quality control are outlined above. Further research may focus on 
the detection of and correction for respiratory motion artifact and suboptimal angulation and slice 
position. In addition, further development of automated quality control of segmentation and other 
analysis results is needed. Quality improvement projects using quasi-experimental designs 
demonstrating the impact of regular automated quality information feedback to radiographers on 
quality of image acquisition could demonstrate the potential of such an approach in population 
studies but also in clinical practice. 
 
Data Sharing 
Despite the large number of participants in each individual study, the clinical goals outlined above 
will only be achieved with a multi-cohort approach that not only allows the inclusion of 
participants from different backgrounds, but also facilitates the link of clinical, laboratory, 
molecular, and clinical data. So far, CAP has helped to establish a large-scale, online accessible 
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database of CMR datasets with associated clinical data [120]. While extremely important, the total 
number of datasets currently included is fewer than 3,000. Therefore, other approaches have been 
developed, most notably euCanSHare [134]. EuCanSHare is a joint EU-Canada project to establish 
a cross-border data sharing and multi-cohort cardiovascular research platform. It currently aims to 
integrate 35 Canadian and European cohorts, making up over 1 million records [134]. Future 
efforts should focus on the development of similar platforms for other regions or, ideally, the 
integration of other cohort studies within euCanSHare. 
 
Sharing and reuse of data and interpretations, particularly in the setting of large-scale population 
datasets, are, however, surrounded by several challenges. Specifically, data must be Findable, 
Accessible, Interoperable, and Reusable, summarized as the FAIR guiding principles recently 
agreed upon by different stakeholders at a Lorentz workshop and summarized by Wilkinson et al. 
[135,136]. These high-level principles are in line with previous work such as the Joint Declaration 
of Data citation Principles [137] or the ‘Data Seal of Approval’ [138], but specifically focus on 
machine actionability – the ability of machines to find and use data, thereby supporting its reuse 
by individuals[139]. Future efforts to share data and make results reproducible should attempt to 
follow this framework and to quantify the level of FAIRness based on 14 defined metrics [140]. 
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Figure 1. Future Work. 
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CONCLUSIONS 
CMR is the reference standard for the assessment of LV and RV anatomy and function. Since the 
start of MESA in 2000, CMR has been used in several large population-based studies, which has 
helped to advance our understanding of the effects of various cardiovascular risk factors on 
myocardial structure and function. The relatively low prevalence of cardiac risk factors and 
outcomes in a general population, however, requires large sample sizes. Two ongoing studies, the 
UK Biobank and the German National Cohort, may help to overcome this limitation due to their 
significantly higher number of CMR scans. 
 
CMR protocols differ between the individual studies. CMR tagging, T1 mapping, and late 
gadolinium enhancement are not universally performed, but have helped to detect subclinical 
disease such as missed MI and have been shown to improve prediction of future cardiovascular 
events.  
 
The reliable and timely analysis of the large number of scans remains an ongoing challenge. While 
automated analyses have been developed that closely match the performance of clinical experts, 
further advances are necessary considering the large sample sizes of the currently ongoing large 
population-based studies. 
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